A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of subcutaneous anakinra (Kineret) in patients with Still's disease (SJIA and AOSD) followed by an open-label extension
|Effective start/end date||1/1/17 → 1/1/21|
- SWEDISH ORPHAN BIOVITRUM AB
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.